Journals / Tüberküloz ve Toraks / 2017 / Cilt: 65 - Sayı: 3

Investigation of parameters related to prognosis in diffuse parenchymal lung diseases prognosis in interstitial lung diseases

Difüz parankimal akciğer hastalıklarında prognozla ilişkili parametrelerin araştırılması

Pages
210–219
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In subgroup analysis for IPF, scleroderma, and RA; 6MWD is only independent factor for mortality

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Parameters related to prognosis in diffuse parenchymal lung disease (DPLD) have a decisive influence on treatment and follow-up processes.
📊
Key Findings & Data:We aimed to define baseline characteristics and factors that effect the mortality of the group of patients with DPLD and to determine distinctions between subgroups.Materials and Methods: Demographic characteristics, complaints, comorbidity, treatment, pulmonary function tests, echocardiographic findings, six minute walking test (6MWT), arterial blood gases analysis, radiological findings and survival time were collected from outpatient clinics database.
💡
Conclusion & Impact:In subgroup analysis for IPF, scleroderma, and RA; 6MWD is only independent factor for mortality
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Parameters related to prognosis in diffuse parenchymal lung disease (DPLD) have a decisive influence on treatment and follow-up processes. We aimed to define baseline characteristics and factors that effect the mortality of the group of patients with DPLD and to determine distinctions between subgroups.Materials and Methods: Demographic characteristics, complaints, comorbidity, treatment, pulmonary function tests, echocardiographic findings, six minute walking test (6MWT), arterial blood gases analysis, radiological findings and survival time were collected from outpatient clinics database. Patients' survival time and mortality-related parameters were evaluated.results: This study consisted of 104 patients. Forty-four of them idiopathic pulmonary fibrosis (IPF), 34 scleroderma and 26 rheumatoid arthiritis (RA) with lung involvement. Mortality rates were similar for the groups but median survival was shorter in patients with IPF than scleroderma and RA (IPF: 35.1 ± 22.4 months, scleroderma: 61.1 ± 27.9 months, RA: 60.0 ± 52.1 months; p= 0.001, p= 0.016 respectively). Mortality was higher in patients who are > 60 years old (24/64 vs. 5/40, p= 0.007), had chronic obstructive pulmonary disease (COPD) (5/7 vs. 24/97, p= 0.017), gastroesophageal reflux (7/13 vs. 22/91 p= 0.043) and usual interstitial pattern (11/48 vs. 18/56, p= 0.054), low PaO (< 60 mmHg) at admission (6/8 vs. 8/32, p= 0.014), desaturation on 6MWT (13/28 vs. 1/18, p= 0.003), high reduction of DLCO/year (6/10 vs. 4/33, p= 0.023). COPD and 6 minute walking distance (6MWD) were found as independently related factors for mortality (p= 0.013, p= 0.02) for whole group.Conclusion: As a result, 6MWD and COPD were found as independently related factors for mortality for all patients. In subgroup analysis for IPF, scleroderma, and RA; 6MWD is only independent factor for mortality

Özet

Difüz parankimal akciğer hastalıklarında prognozla ilişkili parametrelerin araştırılmasıGiriş: Difüz parankimal akciğer hastalıkları (DPAH)'nda prognozla ilişkili parametreler tedavi ve takip süreçlerinde belirleyici öneme sahiptir. Çalışmamızın amacı; DPAH tanısıyla takip edilen hastaların genel özelliklerini, sağkalım sürelerini, mortaliteyle ilişkili faktörleri ve hastalık alt grupları arasındaki farklılıkları saptayabilmektir. Materyal ve Metod: Poliklinik dosyalarından demografik özellikleri, başvuru şikayetleri, ek hastalıkları, aldıkları tedaviler, solunum fonksiyon testleri, ekokardiyografi bulguları, 6 dakika yürüme testleri (6DYT), arter kan gazı sonuçları, radyolojik bulguları, sağkalım süreleri kaydedildi. Hastaların sağkalım süreleri ve mortaliteyle ilişkili parametreler değerlendirildi.Bulgular: Çalışmaya 44 idiopatik pulmoner fibrozis (İPF), 34 skleroderma ve 26 romatoid artrit (RA) akciğer tutulumu olan 104 hasta alındı. İPF, skleroderma ve RA hastalarında mortalite oranları benzerdi. İPF hastalarında median sağkalım süresi skleroderma ve RA hastalarına göre daha kısaydı (İPF'de 35.1 ± 22.4 ay, sklerodermada 61.1 ± 27.9 ay, RA'da 60.0 ± 52.1 ay; p= 0.001, p= 0.016)). İPF, skleroderma ve RA hastalarında mortalite oranları benzerdi. Tüm olgular birlikte değerlendirildiğinde mortalite, > 60 yaş (24/64 vs. 5/40, p= 0.007), kronik obstrüktif akciğer hastalığı (KOAH) (5/7 vs. 24/97, p= 0.017), reflü (7/13 vs. 22/91 p= 0.043), olağan interstisyel pnömoni paterni (11/48 vs. 18/56, p= 0.054), başvuruda düşük PaO (< 60 mmHg) (6/8 vs. 8/32, p= 0.014), 6DYT'de desatürasyon (13/28 vs. 1/18, p= 0.003), birinci yılda anlamlı DLCO kaybı (6/10 vs. 4/33, p= 0.023) olanlarda daha fazla idi. Altı dakika yürüme mesafesi (6DYM) ve KOAH varlığı mortaliteyi bağımsız etkileyen faktörler olarak saptandı (p= 0.013, p= 0.02). Alt grup analizinde 6DYM; İPF, skleroderma ve RA için mortaliteyi etkileyen tek bağımsız parametre olarak bulundu. Sonuç: KOAH varlığı ve 6DYM DPAH'da mortaliteyi bağımsız etkileyen faktörlerdir. İPF, skleroderma ve RA için 6DYM mortaliteyi etkileyen tek bağımsız parametredir

🔖

Cite This Article

ÇAĞATAY, T., KILIÇASLAN, Z., OKUMUŞ, N. G., BİNGÖL, Z., CANIVAR, C. (2022). Investigation of parameters related to prognosis in diffuse parenchymal lung diseases prognosis in interstitial lung diseases. Tüberküloz ve Toraks, Cilt: 65 - Sayı: 3, 210–219. https://ajindex.com/articles/618507

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Tabak L, Kumbasar Ö. Diffüz parankimal akciğer hastalıkları. Türk Toraks Derneği Toraks Kitapları. Sayı 17, Bölüm 1
  2. Özlü T, Metintaş M, Karadağ M, Kaya A. Solunum Sistemi ve hastalıkları temel başvuru kitabı. İstanbul: Medikal Yayıncılık, 2011, Bölüm 5
  3. Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, et al. Radiological versus histological diagnosis in UİP and NSIP: survival implications. Thorax 2003;58:143-8
  4. Nadrous HF, Pellikka P, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, et al. The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest 2005;128:616-7
  5. Woodhead F, Wells AU, Desai SR. Pulmonary complications of connetive tissue diseases. Clin Chest Med 2008; 29:149- 64
  6. Altıay G. Kollajen doku hastalıklarında difüz parankimal akciğer tutulumu. Diffüz Parankimal Akciğer Hastalıkları Toraks Kitapları 2013;17:169-77
  7. Çiftçi F, Köktürk N. Difüzyon testleri, solunum fonksiyon testleri. Toraks Kitapları 56-67
  8. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63 (Suppl 5):S1-58
  9. Novelli F, Tavanti L, Cini S, Aquilini F, Melosini L, Romei C, et al. Determinants of theprognosis of idiopathic pulmonary fibrosis. Eur Rev Med Pharmacol Sci 2014;18:880-6
  10. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vasculer disease-related subtypes. Am J Respir Crit Care Med 2007;175:705-11
  11. Erbes R, Schaberg T, Loddenkenber R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest 1997;111;51-7
  12. Latsi P, Bois R, Nicholson A, Colby TV, Bisirtzoglou D, Nikolakopoulou A, et al. Fibrotic idiopathic interstitial pneumonia, the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med Vol 2003;168:531-7
  13. Flathery KR, Munfort JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8
  14. Zappala JC, Latsi PI, Nicholson AG, Colby TV,Cramer D, Renzoni EA, et al. Marginal decline in forced vital capacity in associated with a poor outcome in idiopathic pulmonary fib